The current GENASSIST offering includes off-the-shelf reagents for using CRISPR editing technology and a kit combination of these reagents to allow customers to generate their own CRISPR-ready cell lines that express Cas9-nickase. According to the company, using such cell lines enables customers to make further modifications to the cell line more efficiently than if they were starting fresh each time. Horizon is also launching a new service for the design, manufacture and validation of CRISPR RNA guides, in an effort to maximize the likelihood that gene editing will occur as expected. Horizon also plans to launch additional products and services as part of GENASSIST.
Dr. Darrin M. Disley, chief executive officer, Horizon Discovery, said, “The launch of our first CRISPR kits mark the next stage in Horizon establishing itself as the leader in the gene editing field. Recent advances in gene editing technology, with techniques such as rAAV, ZFN and CRISPR, have had a revolutionary effect on translational genomics. Horizon’s goal is to make these developments accessible to the wider scientific audience, through contract manufacturing, do-it-yourself products and high-end technical support services.”